361 related articles for article (PubMed ID: 19172550)
1. Baldness, benign prostate hyperplasia, prostate cancer and androgen levels.
Faydaci G; Bilal E; Necmettin P; Fatih T; Asuman O; Uğur K
Aging Male; 2008 Dec; 11(4):189-92. PubMed ID: 19172550
[TBL] [Abstract][Full Text] [Related]
2. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
3. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
4. Reduced circulating androgen bioactivity in patients with prostate cancer.
Raivio T; Santti H; Schatzl G; Gsur A; Haidinger G; Palvimo JJ; Jänne OA; Madersbacher S
Prostate; 2003 May; 55(3):194-8. PubMed ID: 12692785
[TBL] [Abstract][Full Text] [Related]
5. Serum androgens: associations with prostate cancer risk and hair patterning.
Demark-Wahnefried W; Lesko SM; Conaway MR; Robertson CN; Clark RV; Lobaugh B; Mathias BJ; Strigo TS; Paulson DF
J Androl; 1997; 18(5):495-500. PubMed ID: 9349747
[TBL] [Abstract][Full Text] [Related]
6. Androgenetic alopecia and prostate cancer: findings from an Australian case-control study.
Giles GG; Severi G; Sinclair R; English DR; McCredie MR; Johnson W; Boyle P; Hopper JL
Cancer Epidemiol Biomarkers Prev; 2002 Jun; 11(6):549-53. PubMed ID: 12050096
[TBL] [Abstract][Full Text] [Related]
7. Early onset baldness and prostate cancer risk.
Denmark-Wahnefried W; Schildkraut JM; Thompson D; Lesko SM; McIntyre L; Schwingl P; Paulson DF; Robertson CN; Anderson EE; Walther PJ
Cancer Epidemiol Biomarkers Prev; 2000 Mar; 9(3):325-8. PubMed ID: 10750672
[TBL] [Abstract][Full Text] [Related]
8. Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men.
Liu CC; Huang SP; Li WM; Wang CJ; Chou YH; Li CC; Huang CH; Wu WJ
Urology; 2007 Oct; 70(4):677-80. PubMed ID: 17991536
[TBL] [Abstract][Full Text] [Related]
9. Association of benign prostatic hyperplasia with male pattern baldness.
Oh BR; Kim SJ; Moon JD; Kim HN; Kwon DD; Won YH; Ryu SB; Park YI
Urology; 1998 May; 51(5):744-8. PubMed ID: 9610587
[TBL] [Abstract][Full Text] [Related]
10. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
11. Peripheral hormone levels in controls and patients with prostatic cancer or benign prostatic hyperplasia: results from the Dutch-Japanese case-control study.
de Jong FH; Oishi K; Hayes RB; Bogdanowicz JF; Raatgever JW; van der Maas PJ; Yoshida O; Schroeder FH
Cancer Res; 1991 Jul; 51(13):3445-50. PubMed ID: 1711411
[TBL] [Abstract][Full Text] [Related]
12. Androgens and prostate cancer risk: a prospective study.
Wirén S; Stocks T; Rinaldi S; Hallmans G; Bergh A; Stenman UH; Kaaks R; Stattin P
Prostate; 2007 Aug; 67(11):1230-7. PubMed ID: 17562541
[TBL] [Abstract][Full Text] [Related]
13. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
14. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
15. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
16. Patients with a large prostate show a higher prevalence of androgenetic alopecia.
Chen W; Yang CC; Chen GY; Wu MC; Sheu HM; Tzai TS
Arch Dermatol Res; 2004 Nov; 296(6):245-9. PubMed ID: 15517324
[TBL] [Abstract][Full Text] [Related]
17. Androgenetic alopecia and polymorphism of the androgen receptor gene (SNP rs6152) in patients with benign prostate hyperplasia or prostate cancer.
Kucerova R; Bienova M; Kral M; Bouchal J; Trtkova KS; Burdova A; Student V; Kolar Z
J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):91-6. PubMed ID: 24665929
[TBL] [Abstract][Full Text] [Related]
18. Female pattern hair loss may be triggered by low oestrogen to androgen ratio.
Riedel-Baima B; Riedel A
Endocr Regul; 2008 Mar; 42(1):13-6. PubMed ID: 18333699
[TBL] [Abstract][Full Text] [Related]
19. Serum hepatocyte growth factor activator (HGFA) in benign prostatic hyperplasia and prostate cancer.
Nagakawa O; Yamagishi T; Fujiuchi Y; Junicho A; Akashi T; Nagaike K; Fuse H
Eur Urol; 2005 Oct; 48(4):686-90. PubMed ID: 16005141
[TBL] [Abstract][Full Text] [Related]
20. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
